

**Walid Sami Ayoub**  
*Curriculum Vitae*

**PROFESSIONAL CONTACT INFORMATION**

Walid S. Ayoub, MD  
Cedars Sinai Medical Center  
8900 Beverly Blvd., Suite 250  
Los Angeles, CA 90048  
Phone: (310) 423-1971  
Fax: (310)423-2356  
[Walid.Ayoub@cshs.org](mailto:Walid.Ayoub@cshs.org)

**EDUCATION:**

Chemistry, A.S.: Harbor College, Wilmington, CA, 1991-1993.

Biochemistry, B.S.: University of California, Los Angeles, CA, 1993-1995.

M.D.: Creighton University School of Medicine, Omaha, NE, 1995-1999.

Internal Medicine Internship/Residency: UCLA/West Los Angeles Veteran Administration Hospital,  
Los Angeles, CA, 1999-2002.

Hepatology Fellowship: Cedars Sinai Medical Center, Los Angeles, CA, 2002-2004.

Gastroenterology Fellowship: UCLA, Los Angeles, CA, 2004-2006. (One year of the Hepatology  
Fellowship counted toward the GI fellowship).

**LICENSURE:**

California.

**Board Certification:**

ABIM, Internal Medicine, 2002, 2012.

ABIM, Gastroenterology, 2006. 2016.

ABIM, Transplant Hepatology, 2010.

**PROFESSIONAL EXPERIENCE:**

Present position: Associate Medical Director, Liver Transplant Program, Cedars Sinai Medical Center. January 2019-Present.

Professor of Medicine, Cedars Sinai Medical Center.

Health Science Associate Clinical Professor of Medicine, Step 3, UCLA, 2013-Present.

Past position: Clinical Assistant Professor of Medicine, Stanford University, 2006-2012.

Assistant Medical Director, Liver Transplant Program, Cedars Sinai Medical Center. 2012-2018.

Interim Medical Director, Liver Transplant Program, Cedars Sinai Medical Center. January 2018-January 2019.

**PROFESSIONAL ACTIVITIES:**

**Committee Services:**

**Cedars Sinai Medical Center:**

2018-2020: Physician/Nurse Joint Practice Committee

2014-Present. Member. Liver Transplant QA Committee.

2018-Present. Member. Transplant Committee.

2018-Present. Member. Liver Transplant Operational Committee.

2018. Member. 18th Annual Educational Meeting In Gastroenterology, Hepatology Section Organizer and Moderator.

2017. Member. 17th Annual Educational Meeting In Gastroenterology. Hepatology Section Organizer.

2014-2016. Member. Cedars Sinai Liver Transplant EPIC Committee.

2014. Member. Cedars Sinai End of Life Committee.

**American Liver Foundation:**

2017-Present. Member. Medical Advisory Committee.

**American Society of Transplantation (AST)**

2015-Present. AST Liver and Intestinal Community of Practice (LICOP) Committee. 2015-Present.

**American Association for the study of liver diseases (AASLD)**

2015-2017. Member. Hepatology Associates Committee

**Stanford University**

2012. Member. Liver and Intestine Transplant Quality Council. Stanford University, 2012.

2012. Member. Quality Council SRTR Data and Quality Review.

**Professional Associations/Society Memberships**

2004-Present. Member. American Association for the Study of Liver Diseases.

2004-Present. Member. American Gastroenterological Society.

2006-Present. Member. American Liver Foundation.

2012-Present. Member. Southern California Gastroenterology Society.

2014-Present. Member. American Society of Transplantation.

2015-Present. Member. American College of Gastroenterology.

2015-Present. Member. American Society of Transplantation.

**Editorial Services**

**Editor:**

2015-Present Austin Journal of Gastroenterology

**Reviewer:**

2008-present Digestive Diseases and Sciences  
2010-Present American Family Physicians  
2010-Present American Journal of Transplantation  
2013-Present World Journal of transplantation  
2015 Digestive and Liver Diseases  
2015-Present Journal of Liver Transplantation.  
2015-Present Medicine Journal  
2016-Present BMJ Open Gastroenterology  
2017 Transplantation  
2017-Present Journal of Clinical Gastroenterology  
2019-Present Clinical Transplantation

**Community Services**

2007-2012. Volunteer Physician. Pacific Free Clinic-Hepatitis Clinic.

2016: Chairman. IMF-Convent of the Redemption fundraising dinner.

2017. Volunteer Representative to Capitol Hill Day. American Association for the Study of Liver Diseases.

2017. Volunteer Physician. St John Maron Health Fair.

2018: Chairman. St Maron Fundraising Luncheon. Our Lady of Lebanon-St Peter Cathedral.

**HONORS AND SPECIAL AWARDS**

2008-2011. Exceptional Preceptor in Ambulatory Medicine Clerkship. Stanford University.

2016. Top Gastroenterologist in West Hollywood. The Leading Physicians of the World.

2018-2019. Top Gastroenterologist in West Hollywood. The Leading Physicians of the World.

2019. Top Doctors 2019. Consumers' Research Council of America.

**FELLOWSHIP AND RESEARCH GRANTS RECEIVED:**

1. Cangene. Evaluation of HepaGam B in combination with antiviral treatment in hepatitis B liver transplant patients. 2008-2012. Co-PI.
1. Gilead. A Phase IV study to evaluate the efficacy, safety and tolerability of Tenofovir DF in Asian American Adults with chronic hepatitis B infection. 2008. Co-I.
2. Romark. Phase II, Double-Blind, Placebo-Controlled Study of Nitazoxanide in Combination with Peginterferon  $\alpha$ -2a and Ribavirin in Patients with Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin. 2008. Co-I.
3. Eisai. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects with Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures. 2010. Co-PI.
4. Gilead. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection (GS-US-256-0148). 2012. Co-PI.
5. Gilead. A Long Term Follow-up Registry for Subjects who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection (GS-US-248-0122). 2012. Co-I.
6. Gilead. A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection (GS-US-248-0123). 2012. Co-I.
7. Salix. A trial to evaluate the safety and efficacy of Rifaximin with and without lactulose in subjects with a history of hepatic encephalopathy (RFHE4044). 2013. Co-I.
8. Salix. A randomized, double-blind trial, placebo-controlled to evaluate the effects and safety of Rifaximin in subjects with severe liver impairment and hepatic encephalopathy. (RFHE4043). 2013. Co-I.
9. BMS. A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Relapsed on Prior Treatment with Peginterferon Alfa-2a and Ribavirin (AI452020). 2013. Co-I.
10. Vital Therapeutics. A randomized, open-label, multicenter, controlled study to assess safety and efficacy of ELAD in subjects with alcohol induced liver decompensation (AILD) (VTI-208). 2013. Co-I.
11. Gilead. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV (GS-US-342-1138). 2014. 7/1/2014-6/30/2016. CO-I.

12. Galmed Pharmaceuticals Ltd. NASH ARREST Study. A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH). NASH ARREST Study. (NCT02279524). 2015. 12/23/2015-12/22/2018. CO-I.
13. Ocera Therapeutics. Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE). 4/4/2016-4/3/2019. CO-I.
14. Intercept. A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis. 7/14/2016 -7/14/2022. CO-I.
15. Conatus. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis. 8/1/2016-7/31/2017. CO-I.
16. Using Biosensor Data to Predict Frailty in Patients on Liver Transplant List. 2016. CO-I.
17. Microbiome, Microbial Markers, & Liver Disease. 2016. CO-I.
18. Gilead Sciences. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis (GS-US-426-3989). 10/10/2016-9/30/2017. CO-I.
19. Gilead Sciences. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9675 in Subjects with Nonalcoholic Steatohepatitis (GS-US-402-1852). 3/14/2017-3/13/2019. CO-I.
20. Galectin Therapeutics. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis (The NASH-CX Trial). 8/19/2015-8/18/2018. CO-I.
21. NIH/NCI. NWU2015-06-03 Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer. NCI. \$400,208. 9/15/2016-9/14/2018. Co-PI.
22. Gilead Sciences. A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH) (GS-US-416-2124). 5/31/2017-4/30/2018. CO-I.
23. Gilead Sciences. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. 6/14/2017-6/13/2021. Co-I.
24. Gilead Sciences. A Proof of Concept, Open- Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH). 05/14/2017-5/13/2019. CO-I.

25. Zydus Discovery. A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients with Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis. 9/10/2017-09/13/2019. CO-I.
26. Allergan. A Phase 3, Multicenter, Randomizes, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis. 09/10/2017- 09/13/2021. CO-I.
27. NIH/NCI. Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence. 7/6/2017-5/31/2022. CO-PI.
28. Enanta. Randomized, Double Blind, Placebo-Controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Edp-305 In Subjects With Primary Biliary Cholangitis (PBC) With Or Without An Inadequate Response To Ursodeoxycholic Acid (UDCA). 06/06/2018-05/31/2019. PI.
29. Assembly Biosciences. A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731-201 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B. 10/25/18-9/30/2019. PI.
30. Gilead. A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection (GS-US-337-1431). 2/21/2018-10/31/2019. PI.
31. Consortium for Autoimmune Liver Disease. 1/30/2019-. PI.
32. Assembly Biosciences. A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients (ABI-H0731-211). 5/13/19-4/30/2020. PI.
33. Cymabay. A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)- CB8025-31735. 7/10/2019-7/9/2020. PI.

### **Pending Grants:**

1. a.

### **INVITED LECTURES AND PRESENTATIONS:**

#### Clinical Teaching

Cedars Sinai Medical Center

1. Acute Liver Failure and Liver Dialysis. Cedars Sinai Medical Center. Biomedical Science and Translational Medicine Program-GI/Inflammation Core Curriculum. 3/6/2013.

2. Management of Portal Hypertension and listing for liver transplantation. Cedars Sinai Medical Center. 8/27/2013.
3. Liver Emergencies. Cedars Sinai Medical Center. 8/13/2014.
4. Updates in Hepatitis C. 4/9/2015.
5. Jaundice. 6/24/2015.
6. Portal Hypertensive Bleeding. 8/11/2015.
7. Jaundice. 8/19/2015.
8. Jaundice. 10/14/2015.
9. Management of decompensated liver disease. 3/1/2016.
10. Liver Disorders of Copper and Iron Metabolism. 3/15/2016.
11. Varices, Gastropathy and GAVE. 8/2/2016.
12. Evaluation of Jaundice. Medical Student Series. 2/7/2016.
13. Evaluation of Jaundice. Medical Student Series 6//8/2016.
14. Evaluation of Jaundice. Medical Student Series 8/31/2016.
15. Liver emergencies. 9/23/2016.
16. Evaluation of Jaundice. Medical Student Series 10/26/2016.
17. Evaluation of Jaundice. Medical Student Series 6/23/2017.
18. Organ Allocation Policies. 2/7/2017.
19. Inpatient Management of the Cirrhotic Patient. 8/14/2017.
20. Liver emergencies. 10/3/2017.
21. Evaluation of Jaundice. Medical Student Series 10/25/2017.
22. Evaluation of Jaundice. Medical Student Series. 2/21/2018.
23. Liver Emergencies. 7/31/2018.
24. Management of Esophageal and Gastric Varices. 8/7/2018.
25. Acute liver Failure. MICU Lecture Series. 4/5/2019.
26. Liver Emergencies. 7/31/19.



27. Acute liver Failure. MICU Lecture Series. 8/7/2019.
28. Evaluation of Jaundice. Medical Student Series 8/7/2019.

#### UCLA

1. Management of Portal Hypertension, listing for liver transplantation and complications of liver transplantation, UCLA. 8/23/2013.
2. Updates in Hepatitis C. 4/17/2015.

#### Stanford University

1. Hepatitis B: Epidemiology, Prevention and Treatment. Stanford University. 4/07/2007.
2. Introduction to Immunosuppression. Stanford University. 04/08/2007.
3. Esophageal and Gastric Varices: Diagnosis and Treatment. Stanford University. 6/07/2007.
4. Common Presentations and Management Approaches: Acute Liver Failure. Stanford University. 8/8/2008.
5. Hepatic encephalopathy. Bio-X program. Stanford University. 2010.
6. Outpatient Management of Chronic Hepatitis C. Stanford University. 9/25/2012.

#### Non-Clinical Teaching

1. Management of cirrhosis and liver transplantation. Medical Grand Rounds. Enloe Medical Center, Chico CA. 3/17/2011.
2. Update in the management of Hepatitis C. Medical Grand Rounds. Eden Hospital. San Leandro CA. 3/2/2012
3. Update in the Management of Hepatitis C and liver transplantation. Medical Grand Rounds. Dominican Hospital. Santa Cruz CA. 7/13/2012.
4. Hepatitis B Discussion Panel. Post AASLD review. Southern California Gastrointestinal Society. Laguna Beach 2012.
5. HCV Update 2013 and Beyond. 13<sup>th</sup> Annual Educational Meeting in Gastroenterology. Cedars Sinai Medical Center. Los Angeles. 3/1/2013.

6. Ascites: TIPS/Pancreatitis/Surgery. 13<sup>th</sup> Annual Educational Meeting in Gastroenterology. Cedars Sinai Medical Center. Los Angeles. 3/1/2013.
7. Update in Hepatology. Post DDW 2013. Southern California Gastrointestinal Society. Laguna Beach. 6/30/2013.
8. Hepatitis C, liver cancer and HIV/HCV Panel Discussion. Southern California Gastrointestinal Society. Laguna Beach. 6/30/2013.
9. Hepatitis C Panel. Southern California Gastrointestinal Society. Laguna Beach. 12/7/2013.
10. Systemic Diseases and the Liver. 14<sup>th</sup> Annual Educational Meeting in Gastroenterology. Cedars Sinai Medical Center. Los Angeles. 2/28/2014.
11. Early Diagnosis and Treatment of HCC-Case Discussion: Surgical Resection vs. Transplant. Digestive Diseases Week. Chicago. 5/5/2014.
12. Hepatitis C Panel, Post AASLD review. Southern California Gastrointestinal Society. Laguna Beach. 12/14/2014.
13. Liver Summit Program. Cirrhosis and hepatocellular carcinoma. Chronic Liver Disease Foundation. Fountain Valley. 12/17/2014.
14. Hepatology section moderator. 15<sup>th</sup> Annual Educational Meeting In Gastroenterology. Cedars Sinai Medical Center. 3/7/2015.
15. HBV: Can We Have a Cure? 15<sup>th</sup> Annual Educational Meeting In Gastroenterology. Cedars Sinai Medical Center. 3/7/2015.
16. AIH/PBC/PSC Challenges. 15<sup>th</sup> Annual Educational Meeting In Gastroenterology. Cedars Sinai Medical Center. 3/7/2015.
17. Strategies for Hepatitis C Screening Expert Meeting. Lebanon. 10/7/2015.
18. Updates in the Treatment of Hepatitis with the New DAAs. St George Hospital, Balamand Medical School. Lebanon. 10/7/2015.
19. Focus on Treatment of Hepatitis B and C Post Transplantation. Hammoud Hospital. Lebanon. 10/8/2015.
20. Focus on HCV genotype 1. Virology Middle East Expert Meeting. Dubai. 10/9/2015.
21. Update in Viral Hepatitis. 16<sup>th</sup> Annual Educational Meeting In Gastroenterology. Cedars Sinai Medical Center. 3/4/2016.
22. Update in Hepatitis C. Notre Dame de Secours Hospital. Lebanon. 7/15/2016.
23. Challenging Cases in Viral Hepatitis. Cedars Sinai liver transplant conference. Rancho Palos Verdes. 2/12/2017.
24. 17<sup>th</sup> Annual Educational Meeting In Gastroenterology. Hepatology Section Organizer and presenter. 3/3/2017.
25. Update in Liver Cancer. 17<sup>th</sup> Annual Educational Meeting In Gastroenterology. Hepatology Section Organizer and presenter. 3/3/2017.
26. Hepatitis C for the Primary Care. Update in Liver and Kidney Transplant and Hepato-Pancreato-Biliary Surgery. Bakersfield. 3/18/2017.
27. Management of Viral Hepatitis Before and After Solid Organ Transplantation. Moderator. American Transplant Congress. 4/30/2017.
28. Hepatitis B and C for the Primary Care Physicians. Citrus Valley Hospital. 1/30/2018.
29. 18<sup>th</sup> Annual Educational Meeting In Gastroenterology. Hepatology Section Organizer and Moderator. Cedars Sinai Medical Center. 3/3/2018.
30. Update in Liver Cancer. 18<sup>th</sup> Annual Educational Meeting In Gastroenterology. Cedars Sinai Medical Center. 3/3/2018.
31. Update in Viral Hepatitis. Lakewood Regional Medical Center. Lakewood, CA. 3/23/2018.

32. Updates in Management of PBC complications in ESLD. Cedars Sinai liver transplant conference. Rancho Palos Verdes. 4/20/2018.
33. Advances in Management of Cirrhosis and Liver Transplantation. Torrance Memorial Hospital. Torrance, CA. 6/30/2018.
34. New Treatment Options and Strategies for Hepatitis C. Orange Coast Medical Center. 1/24/2019.
35. Advances in NASH. Simply Speaking NASH. CME. Honolulu, HI. 2/8/2019.
36. Updates on Treatment: Hepatitis B and C. West Hills Hospital and Medical Center. West Hills. CA. 2/15/2019.
37. Updates in Cholestatic Liver Diseases. GI Grand Rounds. Cedars Sinai Medical Center. Los Angeles, CA. 3/7/2019.
38. Autoimmune Hepatitis: Update in Management. Cedars Sinai Medical Center. Los Angeles. 3/23/2019.
39. Update on Liver Cancer. Torrance Memorial Hospital. Torrance, CA. 4/3/2019.
40. Marginal Liver Organs: Have We Pushed the Limit? Moderator. American Transplant Congress. 6/5/2019.
41. Updates in The Management of Hepatitis B and C. Providence Holy Cross Medical Center. Mission Hills, CA 10/4/19.
42. Updates on Hepatitis B and C. Los Alamitos Medical Center. Los Alamitos, CA. 10/7/19.

## **PUBLICATIONS:**

### Peer-Reviewed

1. Imatinib (Gleevec) Hepatotoxicity: a Case Report. **Ayoub W**, Poordad F. Journal of Clinical Gastroenterology, 2005; 39, 1:75-77.
2. **Ayoub WS**, Keeffe EB. Management of Hepatitis B in Patients with HBe-Ag Negative Disease. Current Hepatitis Reports, 2008;6,3: 91-95.
3. **Ayoub WS**, Keeffe EB. Current Antiviral Therapy of Chronic HBV infection. Alimentary Pharmacology & Therapeutics, 2008;28,2:167-77
4. **Ayoub WS**, Keeffe EB. Current Management of Chronic Hepatitis B. US Gastroenterology and Hepatology Review. 2008;4,2:28-31.
5. **Ayoub, WS**. Tenofovir - A New Option for the Treatment of Chronic Hepatitis B. Journal of Viral Adaptation. 2009;1:5-10.
6. De Luna W, Sze DY, Ahmed A, Ha BY, **Ayoub W**, Keeffe EB, Cooper A, Esquivel C, Nguyen MH. Transarterial chemoinfusion for hepatocellular carcinoma as down staging therapy and a bridge toward liver transplantation. Am J Transplant. 2009;9,5:1158-68.

- a. I participated in collection and analysis of the data and editing the manuscript.
7. **Ayoub WS**, Esquivel CO, Martin P. Biliary complications following liver transplantation. *Digestive Diseases and Sciences*. 2010; 55 ( 60): 1540-46.
8. **Ayoub WS**, Keeffe EB. Current Antiviral Therapy of Chronic HBV infection. *Alimentary Pharmacology & Therapeutics*, 2011;34,10: 1145-58.
9. Ho EY, Ha NB, Ahmed A, **Ayoub W**, Daugherty T, Garcia G, Cooper A, Keeffe EB, Nguyen MH. Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. *J Viral Hepat* 2012; 19: 2: e105-11.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
10. Ha NB, Ha NB, Ahmed A, **Ayoub W**, Daugherty TJ, Chang ET, Lutchman GA, Garcia G, Cooper AD, Keeffe EB, Nguyen MH. Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. *Cancer Causes Control* 2012;23(3):455-62.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
11. Mair RD, Valenzuela A, Ha NB, **Ayoub WS**, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies. *Clin Gastroenterol Hepatol*. 2012;10,12:1412-17.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
12. Wong RJ, **Ayoub WS**. Current Treatment Strategies for the Management of Chronic Hepatitis B. *JCOM*. 2012;20,1:36-47.
13. Lin H, Ha NB, Ahmed A, **Ayoub W**, Daugherty TJ, Lutchman GA, Garcia G, Nguyen MH. Both HCV and HBV are Major Causes of Liver Cancer in Southeast Asians. *J Immigr Minor Health*. 2013;15,6:1023-29.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
14. Nguyen, LH, Chao D, Lim JK, **Ayoub W**, Nguyen MH. Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis and Systematic Review. Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies. *Clin Gastroenterol Hepatol*. 2014;12,8:1262-6.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.

15. Chao DT, Lim JK, **Ayoub WS**, Nguyen LH, Nguyen MH. Systematic review with meta-analysis: The proportion of Chronic Hepatitis B Patients with Normal ALT  $\leq$  40 IU/L and Significant Hepatic Fibrosis. *Alimentary Pharmacology & Therapeutics*. 2014;39,3:349-58.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
16. Nguyen KD, Sundaram V, **Ayoub WS**. Atypical causes of cholestasis. *World J Gastroenterol*. 2014; 20,28: 9418-9426.
17. Valenzuela A, Ha NB, Gallo A, Bonham C, Ahmed A, Melcher M, Kim LH, Esquivel C, Concepcion W, **Ayoub WS**, Lutchman GA, Daugherty T, Nguyen MN. Recurrent Hepatocellular Carcinoma and Poorer Overall Survival in Patients Undergoing Left-sided Compared With Right-sided Partial Hepatectomy. *Journal of Clinical Gastroenterology*. 2015; 49(2):158-64.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
18. Sundaram V, Choi G, Jeon C, **Ayoub WS**, Nissen NN, Klein AS, Tran T. Donation after cardiac death Liver transplantation in primary sclerosing cholangitis: Proceed with caution. *Transplantation*. 2015;99,5:973-78.
  - a. I participated in analysis of the data and editing the manuscript.
19. Zhang B, Nguyen NH, Yee BE, Yip B, **Ayoub WS**, Lutchman GA, Nguyen MH. Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis. *Intervirology*. 2015;58(4):242-9.
  - a. I participated in analysis of the data and editing the manuscript.
20. Annamalai A, **Ayoub W**, Sundaram V, Bresee B, Klein A. A first look: One year since inception of Regional Share 35 Policy. *Transplant Proceedings*. 2015; 47(6):1585-90.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
21. **Ayoub WS**, Cohen E. Hepatitis B Management in the Pregnant Patient: An Update. *Journal of Clinical and Translational Hepatology*. 2016;4(3):241-247.
22. Annamali A, Chen M, Reich H, Nourredin M, Nissen N, **Ayoub WS**. Advanced Imaging Modalities for Hepatocellular Carcinoma: Is MRI with EOVISt Really Better? *Austin Journal of Gastroenterology*. 2016;3(3):1-6.
23. **Ayoub WS**, Dailey F. Hepatitis C Therapy for Decompensated and Post-Transplant Patients. *Journal of Clinical Gastroenterology*. 2017;51(3):215-222.

24. Thanda Han MA, Saouaf R, **Ayoub W**, Tsuyoshi T, Mena E, Nouredin M. Magnetic Resonance imaging and Transient Elastography in the Management of Nonalcoholic Fatty Liver Disease (NAFLD). *Expert Review of Clinical Pharmacology*. 2017;10(4):379-390.

a. I participated in analysis of the data and editing the manuscript.

25. Sundaram V, Lim J, Tholey D, Iriana S, Kim I, Manne V, Nissen NN, Klein AS, Tran TT, **Ayoub WS**, Schlansky B. The Braden Scale, a standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation. *Liver Transplantation*. 2017;23(9): 1153- 1160.

a. I participated in analysis of the data and editing the manuscript.

26. Ahn J, Sundaram V, **Ayoub W**, Frenette C, Wong RJ. Hypoalbuminemia is associated with significant higher liver transplant waitlist mortality and lower probability. *Journal of Clinical Gastroenterology*. 2018. doi: 10.1097/MCG.0000000000000984. [Epub ahead of print]

a. I participated in analysis of the data and editing the manuscript.

27. **Ayoub WS**, Martin P, Bhamidimarri KR. Hepatitis B virus infection and Organ Transplantation. *Gastroenterol Hepatol* Jan 2018; Volume 12, Issue 1: 33-40.

28. Jacobs PJ, Dong TS, Agopian V, Lagishetty V, Sundaram V, Nouredin M, **Ayoub WS**, Durazo F, Benhammmou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S. Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study. *Hepatology Research*. 2018; 48: 1108-1117. [doi.org/10.1111/hepr.13207](https://doi.org/10.1111/hepr.13207).

29. Sundaram V, Wu, T, Klein AS, Nouredin MD, Kim I, Todo T, **Ayoub WS**, Galloway C, Christianson AL, Nissen N. Liver transplantation for severe alcoholic hepatitis: report of a single center pilot program. *Transplantation Proceedings*. 2018;50:3527-2532.

30. Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, Nouredin M, **Ayoub WS**, Durazo F, Benhammmou J, Enayati P, Elashoff D, Goodman MT, Pisegna J, Hussain S. Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study. *Hepatology research*. 2018;48: 1108-1117.

31. Nouredin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, **Ayoub WS**, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and

Gender Variances. American Journal of gastroenterology. 2018;113:1649-1659.

## Reviews

1. **Ayoub WS**, Keeffe EB. Management of Hepatitis B in Patients with HBe-Ag Negative Disease. *Current Hepatitis Reports*, 2008;6,3: 91-95.
2. **Ayoub WS**, Keeffe EB. Current Management of Chronic Hepatitis B. *US Gastroenterology and Hepatology Review*. 2008;4,2:28-31.
3. Lim, JK, **Ayoub WS**, Nguyen MH. Histologic Disease in Patients with Chronic Hepatitis B, High Viral Load, and Normal Alanine Aminotransferase Levels. *Current Hepatitis Reports*, 2010;9: 65-74.
  - a. I participated in conception of the study, collection and analysis of the data, writing and editing the manuscript.
4. **Ayoub WS**, Lampertico P, Martin P. Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer? *Current Hepatology Reports*. 2015;14(4):279-83.
5. **Ayoub W**, Tram T. Regimens for the Hepatitis C treatment-naïve patient. *Clinical Liver Diseases*. 2015;19 (4):619-27.
6. Management of refractory ascites in cirrhosis: Are we out of date? Alagappan Annamalai, Lauren Wisdom, Megan Herada, Mazen Noureddin, **Walid Ayoub**, Vinay Sundaram, Andrew Klein, Nicholas Nissen. *World Journal of Hepatology*. 2016; 8(28):1182-1193.
  - a. I participated in conception of the study, collection and analysis of the data, and editing the manuscript.
7. Cohen E, **Ayoub WS**. Hepatitis B Management in the Pregnant Patient: An Update. *Journal of Clinical and Translational Hepatology*. 2016; 4:241-247.
8. Dailey F, **Ayoub WS**. HCV Therapy for Decompensated and Post-Transplant Patients. *Journal of Clinical Gastroenterology*. 2017 Mar;51(3):215-222. doi: 10.1097.
9. **Ayoub WS**, Dailey F, Martin P, Jones PD. The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings. *Hepatoma Research*. 2017; 3:302-8.
10. **Ayoub WS**, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current Status of Hepatocellular Carcinoma Detection: Screening Strategies and Novel Biomarkers. *Therapeutic Advances in Medical Oncology*. 2019;\*\*\*\*\*

## Research Papers (Submitted)

Lew D, Cohen E, Guindi M, **Ayoub W**. Acute Seroconversion of Hepatitis C with Near Acute Fulminant Liver Failure. *Digestive Disease Sciences*. Submitted.

## Book Chapters

1. **Ayoub WS**, Keeffe EB. Liver Transplantation: Selection and Listing Criteria. Liver Transplantation for Non Specialist. Barcelona: Permanyer Publications, 2006.
2. **Ayoub WS**. Treatment of Chronic Hepatitis B and C, Gastroenterology Board Review Manual. Hospital Physician. Wayne: Turner White Communications, INC, 2007.
3. **Ayoub WS**, Keeffe EB. Current Treatment of Chronic Hepatitis B. In: GY Wu, K Shetty, eds. Chronic Viral Hepatitis: Diagnosis and Therapeutics. Totowa, NJ: Humana Press, 2008.
4. **Ayoub WS**, Jayasekera CR. Management of Chronic Hepatitis B. In: JT Cox and DI Owen, eds. Hepatitis B: New Research. Nova, 2012.
5. Wong RJ, **Ayoub WS**. Current Treatment Strategies for the Management of Chronic Hepatitis B. In: Hospital Physician Gastroenterology Board Review Manual. Turner White Communication, 2013.
6. **Ayoub, WS**. Determining If and When to Initiate Treatment in the Immunotolerant Patient. In: Critical issues in HBV. Vindico. 2014.

## e-book Chapters

1. Hereditary Hemochromatosis. **Ayoub W**, Martin P. Medscape Gastroenterology, Hepatology Focus, 2003. Available at: <http://www.medscape.com/viewarticle/451324>.
2. Arora G, **Ayoub WS**, Keeffe EB. Percutaneous Liver Biopsy. eMedicine from WebMD. Updated November 10, 2008. Available at: <http://www.emedicine.com/proc/topic149684.htm>.
3. **Ayoub, WS**. The Hepatitis B Treatment Handbook. Medscape Internal Medicine 2012. Available at: <http://www.medscape.org/viewarticle/763116>.
4. **Ayoub WS**, Sundaram V. How to approach non-HBV/HCV hepatitis in clinical practice. The Tarascon Pocket Gastroaedica. 2014.



## Editorials

1. **Ayoub WS**, Keeffe EB. Print and media reviews: Up To Date Liver Practice Guidelines 2007. Web site: [www.uptodate.com](http://www.uptodate.com). Gastroenterology, 2007;133,2:1388-9.
2. **Ayoub WS**, Nguyen MH. Combination of Pharmacologic and Endoscopic Therapy for the Secondary Prevention of Esophageal Variceal Bleeding. Gastrointestinal Endoscopy, 2009;7: 665-667.

## Abstracts

1. Adjuvant Chemotherapy Does Not Affect Survival of Incidental Hepatocellular After Liver Transplantation. **Ayoub W**, Cavazzoni E, Meehan MD, Colquhoun S, Vierling J, Shackleton C, Martin P, Tran T, Poordad F, Nissen N. AASLD 2003.
2. Pre-transplant Adjuvant Therapy for Hepatocellular Carcinoma Results in a Survival Disadvantage. Cavazzoni E, Meehan MD, Shackleton C, Sher L, Vierling JM, Nissen N, Martin P, Poordad F, Tran T, **Ayoub W**, Colquhoun SD. AASLD 2003.
3. Predicting Post-transplant Survival with Hepatocellular Carcinoma: An Assessment of Current Staging Systems and Individual Parameters. Cavazzoni E, Meehan MD, Shackleton C, Sher L, Vierling JM, Nissen N, Martin P, Poordad F, Tran T, **Ayoub W**, Colquhoun SD. AASLD 2003.
4. Non-Invasive Fibrosis Staging in Hepatitis C: Fibrospect versus Liver Biopsy. Simon K, **Ayoub W**, Tran T et al. AASLD, 2003.
5. Living Donor Liver Transplantation: How Much Does It Cost? **Ayoub W**, Poordad F, Tran T. International Liver Transplant Society. 2003.
6. Cryptogenic Cirrhosis: Not Every Case Is Fat. Simon K, Tran T, **Ayoub W**. International Liver Transplant Society. 2003.
7. Morgan M, **Ayoub W**, Ahmed A, Keeffe E, Mindie N. Life-threatening hepatic failure associated with entecavir resistance mutation 1269I/T and T184L two years after discontinuation of lamivudine. AJG, 2007; 102:S322-3.
8. Ha NB, Ahmed A, **Ayoub W**, Daugherty T, Lutchman GA, Garcia, G, Cooper A D, Keeffe, EB, Nguyen, MH. Risk factors (RF) for HCC among patients with underlying liver disease: A prospective study. ASSLD 2010.
9. Nguyen MH, Trinh HN, Garcia RT, Nguyen HA, Nguyen KH, Cooper A, Levitt BS, Keeffe EB, **Ayoub W**, Daugherty T, DaSilveira E, Ahmed A. Low Prevalence of

- Hepatitis B Virus Reverse Transcriptase Mutations in Treatment-Naïve Patients with Chronic Hepatitis B Using INNO-LiPA HBV DR3 in a Multicenter Study. AASLD 2010.
10. Nguyen MH, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, da Silveira E, **Ayoub W**, Garcia G, Ahmed A, Keeffe EB. Hepatitis B virus reverse transcriptase mutations were not detected in treatment-naïve patients with chronic hepatitis B using INNO LiPA HBV DR3: A prospective multicenter study. Digestive Disease Week 2010.
  11. Wong CR, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, **Ayoub W**, Ahmed A, Keeffe EB, Nguyen MH. High Rate of Complete Viral Suppression with Combination Therapy with Tenofovir using Entecavir or Lamivudine/Emtricitabine in Patients with Chronic Hepatitis B and Prior Monotherapy Failure. Oral Presentation at Digestive Disease Week 2010.
  12. Ha NB, Ahmed A, **Ayoub W**, Daugherty T, Lutchman GA, Garcia G, Cooper AD, Gregory PB, Keeffe EB, Nguyen MH. Ethnicity, alcohol consumption, and cigarette use as predictors for hepatocellular carcinoma: a prospective study. Poster of Distinction at Digestive Disease Week 2010.
  13. Mair, RD, Valenzuela A, Ha NB, Ahmed A, **Ayoub WS**, Daugherty T, Lutchman GA, Garcia G, Cooper AD, Keeffe EK, Nguyen, MH. Hepatocellular carcinoma (HCC) incidence in US patients with viral or non-viral etiology of cirrhosis. AASLD 2011.
  14. Yip B, Ha NB, Kim LH, Ahmed A, **Ayoub W**, Cooper AD, Daugherty T, Lutchman GL, Garcia G, Nguyen MH. Ethnic Differences in Clinical Characteristics and Treatments of Asian and Non-Asian With Hepatitis C (HCV)-Related Hepatocellular Carcinoma (HCC). DDW 2012.
  15. Nguyen LH, Cgai DT, Lim JK, **Ayoub W**, Lim J, Nguyen, MH. Meta-Analysis and Systematic Review of Chronic Hepatitis B Patients with Minimally Elevated Alanine Aminotransferase (ALT): Nearly Half with ALT 1-2x Upper Limit of Normal Have Significant Fibrosis. DDW 2013.
  16. Valenzuela Vergara AM, Ha NB, Gallo A, Bonham CA, Melcher ML, Ahmed A, Kim LH, Esquivel CO, Concepcion W, **Ayoub W**, Daugherty T, Lutchman GA, Nguyen MH. Decreased Long-Term Survival in Patients With Hepatocellular Carcinoma (HCC) Following Left-Sided Compared to Right-Sided Partial Hepatectomy. DDW 2013.
  17. Sundaram V, Colquhoun SD, **Ayoub W**, Nissen NN, Klein AS, Tran TT . Higher risk of graft failure and biliary complications for donation after cardiac death liver transplantation in primary sclerosing cholangitis: Analysis of the UNOS database. AASLD 2013.
  18. Chao DT, **Ayoub W**, Lim JK, Nguyen LH, Nguyen MH. Significant fibrosis among patients with chronic Hepatitis B infection and only normal serum alanine transaminase levels: A Systematic Review and Meta-Analysis. AASLD 2013.
  19. Zhang B, Nguyen NH, Yee BE, Yip B, **Ayoub WS**, Nguyen MH, Lutchman GA. Treatment of Acute Hepatitis C (HCV) Infection with Pegylated Interferon and Ribavirin

- (P/R) in Patients Coinfected with Human Immunodeficiency Virus (HIV): a systematic review and meta-analysis. AASLD 2014.
20. Zhang B, Yee B, Nguyen N, Yip B, **Ayoub W**, Nguyen MH, Lutchman GA. Retreatment of Patients With Chronic Hepatitis C Genotype 4 (HCV-4) Infection With Pegylated Interferon and Ribavirin (P/R): A Systematic Review and Meta-Analysis. ACG 2014.
  21. Sundaram V, Patel AV, Alagappan AA, **Ayoub WS**, Tran TT, Klein AS. Obesity and alfa-fetoprotein predict presence of histo-pathologic features associated with hepatocellular carcinoma recurrence after liver transplantation. AASLD 2014.
  22. Anderson J, Annamali AA, Rubinson JL, Tran TT, **Ayoub WS**, Hirschbein J, Voidononikos G, Kim IK, Donchev V, Nissen NN, Klein AS, Sundaram V. Sarcopenia Predicts Mortality after transjugular intrahepatic portosystemic shunt placement. AASLD 2015.
  23. Dailey F, McPhaul C, **Ayoub WS**. A Successful Novel Drug Regimen for Acute Hepatitis C Infection in a Renal Transplant Recipient. ACG 2016.
  24. Syan V, Vu M, McPhaul C, **Ayoub WS**. Disulfiram for Alcohol Cessation: Substituting One Liver Toxin for Another? ACG 2016.
  25. Ahn J, Bhuket T, Liu B, Frenette C, **Ayoub W**, Wong RJ. Less Than One Third of High Risk Patients Eligible for Hepatitis C Virus Screening Received Appropriate Testing: A Community-Based Safety-Net Hospital Experience. ACG 2016.
  26. Lew D, Cohen E, Guindi M, **Ayoub W**. Acute Seroconversion of Hepatitis C with Near Acute Fulminant Liver Failure. ACG 2017.
  27. Ahn J, Sundaram V, **Ayoub W**, Frenette C, Wong RJ. Hypoalbuminemia Is Associated With Significant Higher Liver Transplant Waitlist Mortality And Lower Probability. AASLD 2017.
  28. Shah P, Guindi M, **Ayoub W**. Acute hepatitis in HIV patient. ACP 2018.
  29. Han MAT, Grotts J, Saouaf R, Nouredin N, **Ayoub W**, Scott A, Barbara M, Tjahja M, Okubtoe T, Kayali Z, Mena E, Alkhouri N, Nouredin M. MR Elastography Based Fibrosis Correlates with Clinical Liver Events in Patients with Nonalcoholic Fatty Liver disease (NAFLD): A Multi-Center Study. EASL 2018.
  30. Han, MAT, Grotts JF, Saouaf R, **Ayoub WS**, Scott A, Mansouri M, Barbara M, Tjahja M, Okubtoe TC, Lu SC, Lawitz EJ, Alkhouri N, Nouredin M. MR Elastography Correlates with Liver Outcomes In Patients With Nonalcoholic Fatty Liver Disease (NAFLD): A Multi-Center Study. AASLD 2018.
  31. Nouredin M, Sundaram V, **Ayoub WS**, Han MAT, Grotts J, Saouaf R, Scott A, Mansouri M, Barbara M, Tjahja M, Okubtoe TC, Setiawan VW, Lawitz EJ, Lu SC, Alkhouri N. The

- performance of MRI-Proton Density Fat Fraction (PDFF) and MR Elastography (MRE) in diagnosis of Nonalcoholic steatohepatitis (NASH) Noninvasively. AASLD 2018.
32. Role of Interquartile Range (IQR) of Controlled Attenuated Parameter as a Quality Criteria in Assessing Steatosis via Vibration-Controlled Transient Elastography. AASLD 2019.
  33. A Comprehensive Comparison Of XL vs M Probe In Assessing Steatosis And Fibrosis Via Vibration Controlled Transient Elastography. AASLD 2019
  34. Surgical Treatment Is Associated With Improved Outcome In Patients With Single Less Than 2 cm Hepatocellular Carcinoma. AASLD 2019.
  35. A comprehensive comparison of XL vs M probe in assessing steatosis and fibrosis via vibration controlled transient elastography. AASLD 2019.
  36. Role of interquartile range (IQR) of controlled attenuated parameter as quality criteria in assessing steatosis via vibration controlled transient elastography. AASLD 2019.